West Nile Virus (WNV) is an emerging mosquito-borne human and animal pathogen (NIAID Category B) that has caused outbreaks of fatal encephalitis in Europe, Asia, the Middle East, and most recently, the United States. Despite the increasing numbers of cases and deaths attributed to WNV, no effective therapy or vaccine is available for humans. Recently, using a mouse model of WNV encephalitis, we have demonstrated that a deficiency of antibody leads to disseminated infection, and passive administration of immune serum or purified polyclonal antibody protects antibody-deficient and wild type mice from WNV-induced mortality. Based on these observations, the proposed research plans to generate a new panel of monoclonal antibodies (mAbs) against WNV E and NS1 proteins, test their therapeutic efficacy in our mouse model of WNV encephalitis, and humanize the best candidates for possible clinical intervention.
In Specific Aim 1, a panel of mAbs against the E and NSl proteins of WNV will be generated and characterized for neutralizing activity and effector function, and for localization to discrete structural domains on each protein.
In Specific Aim 2, the mAbs with the greatest inhibitory and effector activity in vitro will be evaluated for therapeutic efficacy in the mouse model of WNV infection. Because the RNA-dependent RNA polymerase of WNV has a high error rate and thus, a potential to rapidly alter immunodominant residues, trials will be also conducted with combinations of mAbs. A novel ranking system has been developed to streamline the selection process of mAbs with the greatest potential inhibitory activity.
In Specific Aim 3, the six anti-E and anti-NS1 mAbs with the greatest inhibitory activity will be humanized using chimerization and complementarily determining region (CDR) grafting techniques and re-evaluated in vitro and in vivo for anti-WNV activity. By studying the mechanisms of antibody-mediated protection, we hope to rationally design immunotherapeutic agents against WNV. These studies are an essential first step in the generation of humanized mAbs that have utility as therapeutic agents against WNV in humans. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project--Cooperative Agreements (U01)
Project #
5U01AI061373-02
Application #
7023796
Study Section
Special Emphasis Panel (ZAI1-AR-M (M1))
Program Officer
Repik, Patricia M
Project Start
2005-03-01
Project End
2010-02-28
Budget Start
2006-03-01
Budget End
2007-02-28
Support Year
2
Fiscal Year
2006
Total Cost
$1,442,808
Indirect Cost
Name
Washington University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Edeling, Melissa A; Austin, S Kyle; Shrestha, Bimmi et al. (2014) Potent dengue virus neutralization by a therapeutic antibody with low monovalent affinity requires bivalent engagement. PLoS Pathog 10:e1004072
Williams, Katherine L; Sukupolvi-Petty, Soila; Beltramello, Martina et al. (2013) Therapeutic efficacy of antibodies lacking Fc? receptor binding against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies [corrected]. PLoS Pathog 9:e1003157
Brien, James D; Sukupolvi-Petty, Soila; Williams, Katherine L et al. (2013) Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus. J Virol 87:7747-53
Pierson, Theodore C; Diamond, Michael S (2012) Degrees of maturity: the complex structure and biology of flaviviruses. Curr Opin Virol 2:168-75
Cox, Jonathan; Mota, Javier; Sukupolvi-Petty, Soila et al. (2012) Mosquito bite delivery of dengue virus enhances immunogenicity and pathogenesis in humanized mice. J Virol 86:7637-49
Austin, S Kyle; Dowd, Kimberly A; Shrestha, Bimmi et al. (2012) Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog 8:e1002930
da Silva Voorham, Júlia M; Rodenhuis-Zybert, Izabela A; Ayala Nuñez, Nilda Vanesa et al. (2012) Antibodies against the envelope glycoprotein promote infectivity of immature dengue virus serotype 2. PLoS One 7:e29957
Shrestha, Bimmi; Austin, S Kyle; Dowd, Kimberly A et al. (2012) Complex phenotypes in mosquitoes and mice associated with neutralization escape of a Dengue virus type 1 monoclonal antibody. Virology 427:127-34
Vogt, Matthew R; Dowd, Kimberly A; Engle, Michael et al. (2011) Poorly neutralizing cross-reactive antibodies against the fusion loop of West Nile virus envelope protein protect in vivo via Fcgamma receptor and complement-dependent effector mechanisms. J Virol 85:11567-80
Brien, James D; Austin, S Kyle; Sukupolvi-Petty, Soila et al. (2010) Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J Virol 84:10630-43

Showing the most recent 10 out of 51 publications